RYTM - RHYTHM PHARMACEUTICALS, INC.
IEX Last Trade
55.85
2.170 3.885%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:11:05 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$53.68
2.17
4.04%
Fundamental analysis
25%
Profitability
25%
Dept financing
12%
Liquidity
75%
Performance
15%
Performance
5 Days
-0.48%
1 Month
-6.79%
3 Months
6.89%
6 Months
30.64%
1 Year
20.50%
2 Year
91.01%
Key data
Stock price
$55.85
DAY RANGE
$53.68 - $55.99
52 WEEK RANGE
$36.01 - $68.58
52 WEEK CHANGE
$12.51
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: David P. Meeker
Region: US
Website: rhythmtx.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: rhythmtx.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Rhythm Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency.
Recent news